Dive into the archives.
- Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, [...]
- What’s the Point of Extavia?
Featured Story Oct. 16, 2009 By Angela Maas, Managing Editor Another drug in the self-injected multiple sclerosis (MS) class recently came onto the marketplace. But many within the pharmaceutical industry are saying that other than giving Novartis an entry into the MS market before its oral MS therapy gains FDA approval, it is unclear what [...]
- First 10-Year Follow-Up Shows That AVONEX® Leads To Long-Term Benefits In Early MS Pts
July 4, 2009 Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients [...]
- Daclizumab and Interferon: Next Wave Combination Therapy?
Studies are ongoing. This post isn’t hot off the press…
- Daclizumab shows Promise in Phase II Trial
Daclizumab Shows Promise in Phase II Trial for MS Just over a year ago, PDL Pharmaceuticals partnered with MS giant Biogen (Avonex, Tysabri) to bring a drug known as daclizumab through trials for MS. Daclizumab is today used for the prevention of kidney transplant rejection, under the marketing name Zenapax (r). The partnership seems to [...]
